Street Calls of the Week
CAMBRIDGE, Mass. - Vyome Holdings, Inc. (NASDAQ:HIND), a micro-cap healthcare company currently valued at $9.01 million and trading at $14.11, announced Monday it has acquired the assets of Oculo, Inc., an artificial intelligence startup founded at MIT, and launched a new business unit focused on developing AI solutions to address inflammation.
The clinical-stage healthcare holding company plans to develop an AI psychiatrist trained on data from both the U.S. and India, aimed at diagnosing and treating systemic inflammation by targeting behavioral drivers and biomarkers.
A newly formed AI subcommittee of Vyome’s board, comprised of MIT alumni Krishna Gupta, Mohanjit Jolly, and Stash Pomichter, will oversee the initiative.
"Inflammation is currently one of the biggest health crises facing humanity, and we intend to attack the condition from all angles in order to limit the usage of steroids," said Pomichter, a Director of Vyome.
The company aims to establish a new therapeutic category combining mental health, psychoneuroimmunology, and digital health, with plans for global commercialization beginning in the U.S. and India.
Alay Shah, founder of Oculo, stated, "I’ve always believed the best AI products would be built firmly with humans in the loop and I’m excited Vyome will carry forth this vision as they target inflammation."
According to Mohanjit Jolly, a Vyome Director and Partner at Iron Pillar, "The market size for digital therapeutics, especially ones that can reduce the reliance on biologics or other drugs, could end up being greater than $100B over the next decade." The company’s stock has shown positive momentum with a 6.53% gain year-to-date, though it remains down 2.86% over the past year. For detailed analysis and growth projections, investors can access the comprehensive research report available on InvestingPro.
Vyome emphasized that the acquisition will not affect progress on its core biotech assets, noting the company remains funded through 2026 to advance its existing business.
The announcement was made in a press release issued by the company.
In other recent news, Vyome Holdings, Inc. announced the completion of its merger with Vyome Therapeutics, making the latter a wholly owned subsidiary. The merger led to the filing of financial statements for the quarter ended June 30, 2025, with the Securities and Exchange Commission. Vyome Holdings also amended its agreement with Maxim Group LLC to increase its at-the-market offering of common stock to $12 million. In a separate development, the company appointed Kreit & Chiu CPA LLP as its new auditor, replacing Haskell & White LLP, and reported no disagreements with the previous firm. Vyome Holdings has entered into a memorandum of understanding with Embryyo Technologies to explore opportunities in the AI-enabled medical device market. Additionally, Vyome’s Phase 2 study of VT-1953 gel showed a significant reduction in malodor for patients with malignant fungating wounds. The company is reviewing strategic options for its majority-owned subsidiary, Livechain Inc., as it explores opportunities on the Nasdaq market. These developments reflect Vyome’s ongoing efforts to expand its market presence and improve its financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.